Cervical cancer represents "the third most common cancer in women around the globe" and causes approximately 300,000 annual deaths. The condition typically stems from persistent human papillomavirus infection, with malignant cells spreading from the cervical surface into deeper tissues.
Early-stage detection enables minimally invasive treatments like cryosurgery and conization. Advanced cases require more substantial surgical intervention, ranging from hysterectomy to pelvic exenteration. Anesthetic selection significantly influences surgical outcomes through effects on immune function and anti-tumor properties.
For hysterectomy procedures, minimally invasive laparoscopic or vaginal approaches produce advantages including reduced blood loss and preserved immune responses compared to open abdominal surgery. Regional anesthesia using nerve blocks or epidural methods demonstrates benefits: "faster return to normal immune function and reduced postoperative pain."
Invasive procedures typically require general anesthesia. Propofol demonstrates anti-inflammatory properties and "longer survival after cancer surgery," while sevoflurane may suppress cervical cancer cell growth through pro-inflammatory mechanisms.
Comprehensive anesthesia management requires preoperative evaluation, perioperative monitoring, postoperative nausea and vomiting prophylaxis, and continued analgesia.